Roche Launches New CE Certified MagNA Pure 96 System for Reliable Nucleic Acid Extraction

Informations

• Publié par: roche-diagnostics-gmbh
• Nombre de lectures: 10
• Langue: English

Extrait

Roche Launches New CE Certified MagNA Pure 96 System for Reliable Nucleic Acid Extraction

PR Newswire PENZBERG, Germany, August 13, 2012

PENZBERG,Germany,August 13, 2012/PRNewswire/ -- Today, Roche announced the launch of its new CE certified IVD version of the MagNA Pure 96 System for automated sample preparation.By providing a maximum of lot-to-lot consistency and highest quality, the new MagNA Pure 96 System is designed to even better fulfill the needs of diagnostic customers. In 2011, the IVD version of MagNA Pure 96 was already introduced in the US. "The proven robustness and unmatched speed of the MagNA Pure 96 System are now available in a CE-marked IVD solution and make the instrument suitable for diagnostic applications in clinical labs around the world," said Gerd Haberhausen, Business Head of qPCR and Nucleic Acid Purification. "This is an important fact for Clinical Research Organizations that operate globally and who need to ensure that clinical trials are based on tools providing consistent quality as well as for global institutions conducting medical research and molecular diagnostic testing." The MagNA Pure 96 System is able to purify a broad spectrum of human samples and offers LIMS (laboratory information management system) connectivity for safer and more convenient data transfer. It provides ready-to- use reagents and uses a minimal number of consumables for purification of nucleic acids from up to 96 clinical samples in less than 60 minutes. The instrument performance characteristics of MagNA Pure have been established in external trials with model parameters. About Roche Headquartered inBasel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over8 billion Swiss francsin R&D. The Group posted sales of42.5 billion Swiss francs. Genentech,United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical,Japan. For more information: http://www.roche.com. All product names and trademarks are the property of their respective owners. For Life Science research only. Not for use in diagnostic procedures For further information please contact: Roche Diagnostics Dr. Claudia Schmitt Phone: [phone] Email: claudia.schmitt.cs2roche.com